. Author manuscript; available in PMC: 2014 Oct 15.

Published in final edited form as: Adv Drug Deliv Rev. 2012 Aug 17;65(10):1331–1339. doi: 10.1016/j.addr.2012.07.012

Table 1.

Improved pharmacokinetic properties by reversible lipidization with palmitic acid.

Lipidized peptide/protein	Linkage	Administration route	Fold increase (vs. non-lipidized)
Lipidized peptide/protein	Linkage	Administration route	AUC^a	Plasma t_1/2
Bowman-Birk Protease Inhibitor [64]	Disulfide	i.v.	11	2
Desmopressin [61]	Disulfide	i.v.	7	n.a.^b
Octreotide [59]	Disulfide	i.v.	8	5
Interferon-α [63]	Disulfide	i.v.	n.a.	5
Calcitonin [62]	Disulfide	s.c.	4	n.a.
Calcitonin [62]	Disulfide	p.o.	19	n.a.
Enkephalin [58]	pH-sensitive	p.o.	21	n.a.

AUC, area under the concentration versus time curve

n.a., data not available